Midodrin Zentiva (Midodrine Hydrochloride)

Midodrine, the active ingredient in Midodrin Zentiva, is an Alpha-1 adrenergic agonist presented as an oral tablet for oral use. It is used to treat orthostatic hypotension in adults who experience a drop in blood pressure upon standing. GNH USA supplies Midodrin Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Midodrine acts on the autonomic regulation of blood pressure and is indicated for conditions that cause a postural drop in blood pressure. - Orthostatic hypotension: improves standing systolic pressure and reduces dizziness or fainting. - Neurogenic orthostatic hypotension: raises blood pressure in patients with autonomic nervous system failure. - Post‑ural hypotension due to medication side‑effects: counteracts drug‑induced blood‑pressure drops.

Midodrine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Piloerection (goose‑flesh) on the arms or torso. - Itching or skin rash. - Urinary retention or difficulty voiding. - Supine hypertension (elevated blood pressure while lying down).

Serious or Rare Side Effects: - Severe hypertension leading to headache or visual disturbances. - Bradycardia or arrhythmias. - Allergic reactions such as angioedema or anaphylaxis. - Myocardial ischemia or infarction in susceptible patients.

Before prescribing Midodrine, clinicians should consider several safety measures. - Blood pressure monitoring: check supine and standing pressures regularly. - Supine hypertension: avoid dosing within 4 hours of bedtime. - Renal impairment: adjust dose or monitor renal function. - Elderly patients: start with the lowest effective dose and titrate slowly. - Abrupt discontinuation: taper to reduce rebound hypotension. - Store at below 25°C: keep in the original pack, protect from moisture.

Midodrine can interact with other agents that affect blood pressure or vascular tone.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other antihypertensive drugs (e.g., clonidine, nitroglycerin): additive blood‑pressure lowering. - Direct vasodilators (e.g., hydralazine): may counteract therapeutic effect.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance orthostatic blood‑pressure changes. - Tricyclic antidepressants: possible additive vasoconstriction. - Selective serotonin reuptake inhibitors (SSRIs): monitor for hypertension. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may affect renal handling of the drug.